$NERV
Minerva Neurosciences Inc

2021 Q1 Form 10-Q Financial Statement

#000156459021026731 Filed on May 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q4 2020 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.250M $3.750M $4.190M
YoY Change 1.43% -2.34% -11.04%
% of Gross Profit
Research & Development $3.259M $3.550M $8.080M
YoY Change -59.67% -87.55% -30.4%
% of Gross Profit
Depreciation & Amortization $0.00 $10.00K $4.367K
YoY Change -100.0% 0.0% 0.0%
% of Gross Profit
Operating Expenses $7.508M $7.300M $12.27M
YoY Change -38.82% -77.45% -24.77%
Operating Profit -$7.508M -$7.299M -$12.27M
YoY Change -38.82% -77.45% -24.77%
Interest Expense $0.00 -$30.00K $120.0K
YoY Change -100.0% -115.0% -75.0%
% of Operating Profit
Other Income/Expense, Net -$1.300M
YoY Change
Pretax Income -$8.800M -$7.320M -$12.15M
YoY Change -27.57% -77.25% -23.25%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$8.805M -$7.324M -$12.15M
YoY Change -27.54% -75.52% -23.23%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$206.0K -$171.4K -$310.1K
COMMON SHARES
Basic Shares Outstanding 42.72M 42.67M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q4 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $80.10M $25.40M $37.50M
YoY Change 113.6% -44.66% -52.65%
Cash & Equivalents $80.14M $25.36M $30.04M
Short-Term Investments $0.00 $7.500M
Other Short-Term Assets $1.500M $2.100M $1.000M
YoY Change 50.0% 61.54% -16.67%
Inventory
Prepaid Expenses $1.983M $851.9K
Receivables
Other Receivables
Total Short-Term Assets $81.70M $27.44M $38.47M
YoY Change 112.39% -41.79% -52.1%
LONG-TERM ASSETS
Property, Plant & Equipment $100.0K $100.0K $11.64K
YoY Change 758.81% 524.57% -97.09%
Goodwill $14.87M $14.87M
YoY Change 0.0%
Intangibles $15.20M $15.20M
YoY Change 0.0%
Long-Term Investments
YoY Change
Other Assets $14.81K $14.81K $14.81K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $30.13M $30.19M $30.33M
YoY Change -0.66% -0.58% -38.72%
TOTAL ASSETS
Total Short-Term Assets $81.70M $27.44M $38.47M
Total Long-Term Assets $30.13M $30.19M $30.33M
Total Assets $111.8M $57.63M $68.80M
YoY Change 62.55% -25.64% -47.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.130M $995.6K $3.000M
YoY Change -62.35% -57.03% 0.0%
Accrued Expenses $2.200M $2.200M $4.100M
YoY Change -46.34% -48.84% 5.13%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.359M $3.160M $7.100M
YoY Change -52.7% -52.33% 2.9%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $61.30M $0.00 $41.20M
YoY Change 48.79% -100.0% -0.48%
Total Long-Term Liabilities $61.30M $0.00 $41.20M
YoY Change 48.79% -100.0% -0.48%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.359M $3.160M $7.100M
Total Long-Term Liabilities $61.30M $0.00 $41.20M
Total Liabilities $66.46M $4.964M $50.20M
YoY Change 32.39% -90.02% -4.2%
SHAREHOLDERS EQUITY
Retained Earnings -$344.5M -$284.8M
YoY Change -0.68%
Common Stock $339.0M $337.5M
YoY Change 7.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $45.37M $52.66M $18.62M
YoY Change
Total Liabilities & Shareholders Equity $111.8M $57.63M $68.80M
YoY Change 62.55% -25.64% -47.0%

Cashflow Statement

Concept 2021 Q1 2020 Q4 2020 Q1
OPERATING ACTIVITIES
Net Income -$8.805M -$7.324M -$12.15M
YoY Change -27.54% -75.52% -23.23%
Depreciation, Depletion And Amortization $0.00 $10.00K $4.367K
YoY Change -100.0% 0.0% 0.0%
Cash From Operating Activities -$5.217M -$7.160M -$9.202M
YoY Change -43.3% -49.51% -4.15%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $17.03M
YoY Change -100.0% -100.0% -261.42%
Cash From Investing Activities $0.00 $0.00 $17.03M
YoY Change -100.0% -100.0% -261.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 60.00M 0.000 797.6K
YoY Change 7422.29% 51.93%
NET CHANGE
Cash From Operating Activities -5.217M -7.160M -9.202M
Cash From Investing Activities 0.000 0.000 17.03M
Cash From Financing Activities 60.00M 0.000 797.6K
Net Change In Cash 54.78M -7.160M 8.624M
YoY Change 535.27% -56.61% -143.94%
FREE CASH FLOW
Cash From Operating Activities -$5.217M -$7.160M -$9.202M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
14808
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
58953
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1129627
CY2021Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
15200000
CY2021Q1 us-gaap Goodwill
Goodwill
14869399
CY2021Q1 us-gaap Assets
Assets
111832378
CY2021Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
2164657
CY2020Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
2053409
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
64350
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
14808
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
101786
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
15200000
CY2020Q4 us-gaap Goodwill
Goodwill
14869399
CY2020Q4 us-gaap Assets
Assets
57626209
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
995614
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
111229
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
3358634
CY2021Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1803356
CY2021Q1 nerv Liability Related To The Sale Of Future Royalties
LiabilityRelatedToTheSaleOfFutureRoyalties
61296456
CY2021Q1 us-gaap Liabilities
Liabilities
66458446
CY2020Q4 us-gaap Liabilities
Liabilities
4963608
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42721566
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42721566
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42721566
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
7507521
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
12271578
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7507521
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-12271578
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
4272
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42721566
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
45373932
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
4272
CY2021Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
338969840
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
337453776
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-293600180
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-284795447
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
45373932
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
52662601
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
111832378
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
57626209
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5217359
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9202397
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-4856
CY2020Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-9392
CY2020Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
129805
CY2021Q1 nerv Non Cash Interest Expense For The Sale Of Future Royalties
NonCashInterestExpenseForTheSaleOfFutureRoyalties
1296456
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
27779543
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
797629
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
18624194
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1516064
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-8804733
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-8804733
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-12151165
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4367
CY2020Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
64959
CY2021Q1 us-gaap Amortization Of Leased Asset
AmortizationOfLeasedAsset
42833
CY2020Q1 us-gaap Amortization Of Leased Asset
AmortizationOfLeasedAsset
38449
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1516064
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2198187
CY2021Q1 nerv Non Cash Interest Expense For Sale Of Future Royalties
NonCashInterestExpenseForSaleOfFutureRoyalties
1296456
CY2021Q1 nerv Increase Decrease In Prepaid Expense Other Current Assets
IncreaseDecreaseInPrepaidExpenseOtherCurrentAssets
-533639
CY2020Q1 nerv Increase Decrease In Prepaid Expense Other Current Assets
IncreaseDecreaseInPrepaidExpenseOtherCurrentAssets
-330619
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
134013
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
686050
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
111248
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-202930
CY2021Q1 nerv Increase Decrease In Operating Lease Liabilities Current
IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent
-46879
CY2020Q1 nerv Increase Decrease In Operating Lease Liabilities Current
IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent
5864
CY2020Q1 nerv Increase Decrease In Operating Lease Liabilities Noncurrent
IncreaseDecreaseInOperatingLeaseLiabilitiesNoncurrent
-46879
CY2020Q1 us-gaap Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
20900000
CY2020Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
3871706
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
17028294
CY2021Q1 nerv Proceeds From Sale Of Future Royalties
ProceedsFromSaleOfFutureRoyalties
60000000
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
797629
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
60000000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
797629
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
54782641
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8623526
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
25456952
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
21512623
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
80239593
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
30136149
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
80139593
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30036149
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-293600000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5200000
CY2021Q1 nerv Cash Cash Equivalents Restricted Cash And Marketable Securities
CashCashEquivalentsRestrictedCashAndMarketableSecurities
80200000
CY2021Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
100000
CY2020Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
100000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
80239593
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30136149
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. </p>
CY2021Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
100000
CY2020Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
100000
CY2020Q4 nerv Accrued Research And Development Costs And Other Expenses Current
AccruedResearchAndDevelopmentCostsAndOtherExpensesCurrent
1880552
CY2021Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
206089
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
140981
CY2021Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
Concentration of credit risk <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents and marketable securities. The Company maintains its cash and cash equivalent balances in the form of business checking accounts and money market accounts, the balances of which, at times, may exceed federally insured limits. Exposure to cash and cash equivalents credit risk is reduced by placing such deposits with major financial institutions and monitoring their credit ratings. Marketable securities consist primarily of corporate bonds, with fixed interest rates. Exposure to credit risk of marketable securities is reduced by maintaining a diverse portfolio and monitoring their credit ratings.</p>
CY2021Q1 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
CY2021Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2021Q1 nerv Liability Related To The Sale Of Future Royalties
LiabilityRelatedToTheSaleOfFutureRoyalties
61296456
CY2021Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q1 nerv Accrued Research And Development Costs And Other Expenses Current
AccruedResearchAndDevelopmentCostsAndOtherExpensesCurrent
1461612
CY2021Q1 us-gaap Accrued Vacation Current
AccruedVacationCurrent
61268
CY2021Q1 nerv Accrued Severance Current
AccruedSeveranceCurrent
15938
CY2020Q4 nerv Accrued Severance Current
AccruedSeveranceCurrent
31876
CY2021Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
2164657
CY2020Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
2053409
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-8804733
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-12151165
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42721566
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39177592
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31
CY2021Q1 nerv Liability Related To The Sale Of Future Royalties
LiabilityRelatedToTheSaleOfFutureRoyalties
60000000
CY2021Q1 nerv Annual Interest Rate On Interest Expense
AnnualInterestRateOnInterestExpense
0.105
CY2021Q1 nerv Upfront Payment Paid
UpfrontPaymentPaid
60000000
CY2021Q1 nerv Non Cash Interest Expense For Sale Of Future Royalties
NonCashInterestExpenseForSaleOfFutureRoyalties
1296456
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2198187
CY2016Q1 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
200000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.14
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
300000
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1516064
CY2020Q4 nerv Retention Program Description
RetentionProgramDescription
each participant other than the Company’s Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”) are eligible to receive a guaranteed cash retention bonus equal to 50% of such participant’s target bonus for 2021 (which target bonus will be no less than such participant’s target bonus for 2020) to be paid on July 31, 2021

Files In Submission

Name View Source Status
0001564590-21-026731-index-headers.html Edgar Link pending
0001564590-21-026731-index.html Edgar Link pending
0001564590-21-026731.txt Edgar Link pending
0001564590-21-026731-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nerv-10q_20210331.htm Edgar Link pending
nerv-10q_20210331_htm.xml Edgar Link completed
nerv-20210331.xsd Edgar Link pending
nerv-20210331_cal.xml Edgar Link unprocessable
nerv-20210331_def.xml Edgar Link unprocessable
nerv-20210331_lab.xml Edgar Link unprocessable
nerv-20210331_pre.xml Edgar Link unprocessable
nerv-ex101_185.htm Edgar Link pending
nerv-ex102_184.htm Edgar Link pending
nerv-ex103_183.htm Edgar Link pending
nerv-ex311_7.htm Edgar Link pending
nerv-ex312_6.htm Edgar Link pending
nerv-ex321_8.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending